RECRUITING

Impact of Supplemental Fiber on Gut and Vascular Health Related in Obesity Phenotypes

Description

Based on prior research, the investigators are interested in whether an intervention targeting gut health (supplemental fiber for 9 weeks total) will improve vascular health in individuals with obesity. Additionally, the investigators are interested in if this response differs based on whether individuals with obesity have very few heart disease risk factors or several heart disease risk factors.

Conditions

Metabolic SyndromeHealthy ParticipantsMetabolically Healthy ObesityMetabolically Abnormal Obesity
Talk to us

Related Conditions:

Metabolic SyndromeHealthy ParticipantsMetabolically Healthy ObesityMetabolically Abnormal Obesity

Study Overview

On this page

Study Details

Study overview

Based on prior research, the investigators are interested in whether an intervention targeting gut health (supplemental fiber for 9 weeks total) will improve vascular health in individuals with obesity. Additionally, the investigators are interested in if this response differs based on whether individuals with obesity have very few heart disease risk factors or several heart disease risk factors.

Interplay Between Metabolic Risk Factors, Body Mass Index, and the Gut/Vascular Response to Supplemental Fiber

Impact of Supplemental Fiber on Gut and Vascular Health Related in Obesity Phenotypes

Condition
Metabolic Syndrome
Intervention / Treatment

-

Contacts and Locations

Muncie

Health Professions Building, Muncie, Indiana, United States, 47306

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Participants are 18-55 years old.
  • * Participants BMI is ≥30 kg/m2 - this BMI requirement is due to our research aims.
  • * Participants have either 0-1 or 2+ of the following risk factors outside of the normal reference ranges: blood pressure, blood sugar, triglycerides, and HDL-cholesterol.
  • * Participants are not pregnant or expecting to become pregnant (females only). •Participants are not postmenopausal (females only).
  • * Participants have not been diagnosed with an advanced cardiometabolic condition (e.g., cardiovascular disease, type 2 diabetes).
  • * Participants have not been diagnosed with a chronic inflammatory condition (e.g., rheumatoid arthritis, inflammatory bowel disease, diverticulosis/diverticulitis).
  • * Participants do not regularly take anti-inflammatory drugs (more than 2x week) and are willing to suspend use of these medications for 3 days leading up to in-lab visits.
  • * Participants do not take weight-loss medications (e.g., Ozempic, Wegovy).
  • * Participants do not use tobacco products or any illicit drugs.
  • * Participants have not used antibiotics or probiotics in the last month.
  • * Participants do not have dietary restrictions prohibiting them from consuming the fiber supplement (e.g., food allergies/intolerance).
  • * Participants do not have a pacemaker.
  • * Participants are able to lie on their back (supine position) in the dark for at least 10 minutes (related to vascular measurements).
  • * Participants are not 18-55 years old.
  • * Participants BMI is not ≥30 kg/m2 - this BMI requirement is due to our research aims.
  • * Participants do not have either 0-1 or 2+ of the following risk factors outside of the normal reference ranges: blood pressure, blood sugar, triglycerides, and HDL-cholesterol.
  • * Participants are pregnant or expecting to become pregnant (females only).
  • * Participants are postmenopausal (females only).
  • * Participants have been diagnosed with an advanced cardiometabolic condition (e.g., cardiovascular disease, type 2 diabetes).
  • * Participants have been diagnosed with a chronic inflammatory condition (e.g., rheumatoid arthritis, inflammatory bowel disease, diverticulosis/diverticulitis). •Participants regularly take anti-inflammatory drugs (more than 2x week) and are not willing to suspend use of these medications for 3 days leading up to in-lab visits.
  • * Participants take weight-loss medications (e.g., Ozempic, Wegovy).
  • * Participants use tobacco products or any illicit drugs.
  • * Participants have used antibiotics or probiotics in the last month.
  • * Participants have dietary restrictions prohibiting them from consuming the fiber supplement (e.g., food allergies/intolerance).
  • * Participants have a pacemaker.

Ages Eligible for Study

18 Years to 55 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Ball State University,

Bryant Keirns, PhD, PRINCIPAL_INVESTIGATOR, Ball State University

Study Record Dates

2027-05